Archive · 20 Aug 2026
Moderna Shares Surge After Positive Personalized Melanoma Trial Results
Moderna and Merck tested a special cancer treatment made for each person’s tumor.
The treatment uses mRNA to help the immune system recognize and attack cancer cells.
It was tested with Merck’s Keytruda drug in people with high-risk melanoma.
Their large trial met its main goals, including keeping the cancer from returning for longer.
It also delayed the spread of cancer in another measurement.
Investors liked the news, so Moderna’s shares rose sharply.
However, the companies have not shown all the trial data yet.
The treatment still needs approval and may be difficult and expensive to make for many people.
Moderna shares rose 177% to $174.38 after positive late-stage melanoma trial results.
The personalized mRNA treatment, intismeran, is tailored to mutations in each patient’s tumor.
The Phase 3 trial involved 1,137 patients and delayed melanoma recurrence and spread.
Moderna and Merck have not yet released detailed findings and still need regulatory approval.
The results could give Moderna a new growth path as demand for COVID-19 vaccines declines.
- Who
- Moderna and Merck, with the treatment tested in 1,137 melanoma patients.
- What
- A Phase 3 trial of the personalized mRNA cancer treatment intismeran met its main and secondary goals.
- When
- The share-price reaction occurred on August 19; the companies plan to present detailed trial results later this year.
- Where
- The market reaction occurred in US trading, while the article does not specify the trial’s location.
- Why
- The results could delay melanoma recurrence and spread and give Moderna a new business beyond COVID-19 vaccines.
Investor optimism
Clinical and regulatory caution
Commercial potential
Investor optimism
The trial could show that Moderna’s mRNA platform can support a major business beyond infectious diseases and declining COVID-19 vaccine demand.
Clinical and regulatory caution
A successful trial does not guarantee approval, widespread use, or a commercially viable product.
Evidence from the trial
Investor optimism
The Phase 3 study met its main goal and a secondary goal measuring the time before cancer spread.
Clinical and regulatory caution
The detailed results have not been released, so researchers and investors still need to assess the underlying data.
Manufacturing and access
Investor optimism
An approved personalized treatment could create a new cancer-treatment market and potentially support Merck’s Keytruda business.
Clinical and regulatory caution
Producing treatments tailored to individual tumors on a large scale could be expensive and complicated.
- Treatment
- Intismeran, a personalized mRNA-based therapy designed around mutations in each patient’s tumor.
- Trial stage
- Phase 3, or late-stage clinical testing.
- Participants
- 1,137 people with high-risk melanoma whose tumors had been surgically removed.
- Trial results
- The study met its main goal of extending the time before melanoma returned and a secondary goal involving cancer spread.
- Moderna share move
- Shares rose 177% to $174.38 on August 19.
- Merck share move
- Merck shares rose more than 12% after the results.
- Next steps
- Detailed findings will be presented later this year, followed by regulatory submissions; Moderna is targeting a US launch next year if approved.